Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.

In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.

Zhitong FinanceFeb 13 22:11 ET

Positive Earnings Growth Hasn't Been Enough to Get 3SBio (HKG:1530) Shareholders a Favorable Return Over the Last Five Years

Simply Wall StFeb 12 23:56 ET

[Brokerage Focus] CMB International indicates that China Meheco Group has started a valuation recovery.

Jinwu Financial News | China Merchants International states that the MSCI Chinese Medical Index has risen 5.3% year-to-date as of early 2025, outperforming the MSCI Chinese Index by 0.9%. Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a highly elastic industry, is expected to outperform the market in 2025. The Category C medical insurance directory is set to be implemented within the year, and Innovative Drugs will benefit from better payment conditions through commercial health insurance coverage. The bidding for Medical Devices is accelerating its recovery, which will drive the profit recovery of domestic medical device companies. The bank is Bullish about the recovery of industry valuations. It recommends buying WUXI APPTEC (02359, 603259 CH).

King Wu Financial NewsFeb 10 01:45 ET

Zhaoyin International: Bullish on the valuation repair of the China Meheco Group Industry, recommending to Buy WUXI APPTEC (02359) and others.

Cinda International believes that China will become a necessary place for overseas pharmaceutical companies to seek innovative drug pipelines, and innovative drugs from China will play an increasingly important role on the international stage.

Zhitong FinanceFeb 9 20:46 ET

Hong Kong stocks movement | 3SBIO (01530) rose nearly 3%. The company recently announced multiple early clinical pipelines and plans to start the SSS40 Phase II clinical trial in February.

3SBIO (01530) rose nearly 3%, and as of the time of this report, it is up 2.11%, priced at 6.28 Hong Kong dollars, with a transaction amount of 25.2434 million Hong Kong dollars.

Zhitong FinanceFeb 5 22:32 ET

[Brokerage Focus] Zhuhai International maintains a "Buy" rating for 3SBIO (01530), indicating that its innovative pipeline has the potential for overseas expansion.

Jinwu Financial News | Zhāo Yín International released a Research Report indicating that 3SBIO (01530) recently announced early phase II clinical data for 707 (PD-1/VEGF): 1) In the monotherapy first-line treatment trial for PD-L1+, EGFR/ALK WT NSCLC, the 10mg/kg Q3W dosage group had 24 patients who underwent at least 2 tumor assessments, with an ORR of 70.8%, which is higher than the results for Iwosizumab (AKESO, AK112) in the phase Ib (HARMONi-5, Link) and phase III (HARMONi-2, Link) clinical trials.

Jinwu Financial NewsFeb 3 00:56 ET

China Merchants Bank International: Maintains 3SBIO 'Buy' rating as early clinical data for PD-1/VEGF dual antibody is announced.

CMB International released a Research Report stating that it maintains a "Buy" rating for 3SBIO (01530) with a Target Price of HKD 9.91, believing the Company Valuation is attractive, profit growth is stable, and the innovation pipeline has potential for expansion abroad. It is expected that the company's revenue and Net income will grow by 12% and 13% year-on-year respectively by 2025. Based on a 9-year DCF model, a Target Price of HKD 9.91 is given (WACC: 12.20%, perpetual growth rate: 2.0%), corresponding to a PE of 10.0 times for 2025. CMB International's main points are as follows: 707 (PD-1/VEGF) demonstrates excellent potential.

Sina Hong Kong Stock.Feb 2 23:02 ET

CMB International: Maintains the "Buy" rating for 3SBIO (01530) as early clinical data for PD-1/VEGF dual antibody is announced.

The early clinical data of the PD-1/VEGF dual antibody has been released, demonstrating potential for superior efficacy.

Zhitong FinanceFeb 2 22:41 ET

China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.

National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.

Zhitong FinanceJan 20 18:54 ET

WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.

① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?

cls.cnJan 20 03:30 ET

Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.

In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.

Zhitong FinanceJan 20 00:51 ET

Zhao Yin International: The Class B medical insurance catalog will be implemented within the year, Innovative Drugs will open up domestic payment space.

Zhao Yin International is Bullish on the valuation recovery of the Medical and Pharmaceutical Industry.

Zhitong FinanceJan 19 20:38 ET

What does AI pharmaceuticals still lack before a market explosion? | Focus

① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.

cls.cnJan 19 19:34 ET

Sentiment Still Eluding 3SBio Inc. (HKG:1530)

Simply Wall StJan 17 17:01 ET

Hong Kong stock movement | 3SBIO (01530) rises over 4% after obtaining commercialization rights for multiple indications of the HER2 ADC drug DB-1303 developed by Yingen Biotechnology.

3SBIO (01530) rose over 4%. As of the time of writing, it increased by 4.01%, reaching 5.96 Hong Kong dollars, with a transaction amount of 47.4687 million Hong Kong dollars.

Zhitong FinanceJan 16 01:10 ET

3SBio Unit Gets Commercialization Rights for Duality Biologics' Cancer Drug in China, Hong Kong, Macau

MT NewswiresJan 13 07:16 ET

3SBIO (01530.HK) has reached a collaboration with InnoCare Pharma regarding the HER2ADC drug.

On January 13, Glonghui reported that 3SBIO (01530.HK) announced that its subsidiary Shenyang 3SBIO Co., Ltd. ("Shenyang 3SBIO") and its subsidiaries have reached a cooperation agreement with Ying'en Biotechnology (Shanghai) Co., Ltd. ("Ying'en Biotechnology"), a clinical-stage innovative biopharmaceutical company focused on developing next-generation ADC therapeutic drugs for patients with cancer and autoimmune diseases, regarding the HER2 ADC drug DB-1303. The agreement stipulates that Shenyang 3SBIO will obtain multiple indications for Ying'en Biotechnology's developed HER2 ADC drug DB-1303 in mainland China.

Gelonghui FinanceJan 13 04:20 ET

Express News | 3Sbio - Cooperation Between 3Sbio Inc. and Duality Biologics in Respect of Her2 ADC Drug

ReutersJan 13 04:17 ET

China Securities Co.,Ltd.: An outlook on the pharmaceutical Industry 2024 annual report.

In 2025, the Industry is expected to achieve moderate growth and overall move towards high-quality development.

Zhitong FinanceJan 12 20:37 ET

Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.

The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.

Zhitong FinanceJan 9 21:20 ET